Letrozole, Abemaciclib, and Metformin Triplet Therapy Shows Robust Activity in ER-Positive Endometrioid Endometrial Cancer
Posted innews OB/GYN & Women’s Health Oncology

Letrozole, Abemaciclib, and Metformin Triplet Therapy Shows Robust Activity in ER-Positive Endometrioid Endometrial Cancer

A phase 2 trial demonstrates that combining letrozole, abemaciclib, and metformin achieves a 32% response rate and 60% clinical benefit rate in ER+ endometrioid endometrial cancer, with notable efficacy in CTNNB1-mutated tumors and an interesting pharmacokinetic interaction increasing metformin exposure.
Breast Cancer Index in Premenopausal HR+ Disease: Prognostic Confirmed, Predictive Role for OFS-Intensification Context-Dependent
Posted innews Oncology

Breast Cancer Index in Premenopausal HR+ Disease: Prognostic Confirmed, Predictive Role for OFS-Intensification Context-Dependent

Two large prospective‑retrospective analyses confirm BCI as a robust prognostic biomarker in premenopausal HR+ breast cancer; its HOXB13/IL17BR (H/I) component predicted benefit from adding ovarian function suppression versus tamoxifen alone but did not clearly predict superiority of exemestane+OFS over tamoxifen+OFS.